Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|20 CitationsCognitive & SleepFemale-friendly

DSIP Dosing Protocol: Sleep Enhancement Guide

Also known as: Delta Sleep-Inducing Peptide, Slow-Wave Sleep Nonapeptide

Dose Range
25–100 mcgResearch range
0Typical research window: 25–100 mcg150 mcg

Studied in published research — not a medical recommendation. Primary protocol (Sleep Enhancement Protocol): 25-100 mcg, 30 minutes before bedtime.

Protocol at a Glance
How Often
30 minutes before bedt

30 minutes before bedtime

A Typical Run
4-6 weeks

Research-reported range; the linked study used a different dose or units. Higher sleep efficiency and shorter sleep latency demonstrated in clinical trials

How It's Taken
Vial

Subcutaneous or intranasal

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 25 mcg1 units
High end: 100 mcg4 units

All U-100: 100 units = 1 mL. 200 doses in the vial at the low end (50 doses at the high end).

Track the doses you run

Save DSIP (Delta Sleep-Inducing Peptide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

DSIP (Delta Sleep-Inducing Peptide) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$30.00 net$60.00
10mg Lyophilized Vial
$3.00/mg$6.00/mg retail
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$49.00
10mg vial
$4.90/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$55.00
10mg vial
$5.50/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$63.00
10mg vial
$6.30/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-3123996 (99.14%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$75.00
10mg vial
$7.50/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$76.99
10mg vial
$7.70/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$40.00
5mg vial
$8.00/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$41.00
5mg vial
$8.20/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$44.00
5mg vial
$8.80/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$55.97
5mg vial
$11.19/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Synthetic Bioactive Signaling Peptide
Administration Route
Intranasal spray (mucosal BBB delivery) or Under-the-skin injection (SubQ)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring peptide that promotes sleep. It was isolated from rabbit brain in 1977. Limited modern clinical trials but some evidence for sleep quality improvement.

Best evidence for

Sleep quality, sleep regulation

Weakest evidence for

Insomnia treatment (severe), anxiety

Pharma equivalent

None

Studies on file

20 (9 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. DSIP (Delta Sleep-Inducing Peptide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

DSIP is a naturally occurring nonapeptide that was first isolated from rabbit cerebral venous blood during slow-wave sleep. It acts as a neuromodulator and has been shown to increase sleep efficiency, reduce sleep latency, and provide neuroprotective effects through antioxidant mechanisms.

Mechanisms of Action

  • Modulates NMDA receptor activity in the brain
  • Increases GABAergic transmission
  • Stimulates acetyltransferase activity through α1 receptors
  • Enhances superoxide dismutase (SOD) and glutathione peroxidase activity
  • May regulate circadian rhythms through hypothalamic action

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Sleep Enhancement Protocol
reported protocol
25-100 mcg30 minutes before bedtime4-6 weeksSubcutaneous or intranasalhuman
Recovery/Stress Protocol
reported protocol
100-200 mcgDaily for 10 days, then as needed10-day cyclesSubcutaneousanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (DSIP (Delta Sleep-Inducing Peptide))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

9 Human11 Animal

Quite 100% of DSIP has been entrapped into positively charged Co-DMAEMA-MBAA matrix, while the quantity of DSIP adsorbed on negatively charged Co-AA-MBAA was only 2-6%. DSIP release from Co-DMAEMA-MBAA was observed in saline solutions (0.9% NaCl and PBS) while there was no DSIP release in water or 25% ethanol, thus ionic strength was a reason of this process.

Limitations: Animal study only — human translation uncertain.

2015|Materials science &amp; engineering. C, Materials for biological applications
PubMed

ACTH (4-10) analogue injection inhibited stress-induced Fos expression in the pPVN and the medial septum, but only in predisposed rats. The experiments indicate that DSIP and ACTH (4-10) analogue reduce pPVN and limbic neurone responses to emotional stress in the rats predisposed to emotional stress; the effects on Fos expression may play a role in the biological activities of these peptides.

Limitations: Animal study only — human translation uncertain.

2012|Stress (Amsterdam, Netherlands)
PubMed

This assumption is based on: (i) a highly specific distribution of DSIP-like immunoreactivity in the neurosecretory hypothalamic nuclei of various vertebrate species that are not particularly relevant for sleep regulation, as revealed by the histochemical studies of the Geneva group (Charnay et al.); (ii) a large spectrum of DSIP biological activity revealed by biochemical and physiological studies in vitro; (iii) significant slow-wave sleep (SWS) promoting activity of certain artificial DSIP structural analogues (but not DSIP itself!) in rabbits and rats revealed by our early studies; and (iv) significant SWS-promoting activity of a naturally occurring dermorphin-decapeptide that is structurally similar to DSIP (in five of the nine positions) and the sleep-suppressing effect of its optical isomer, as revealed in rabbits. Potential future studies are outlined, including natural synthesis and release of this DSIP-like peptide and its role in neuroendocrine regulation.

Limitations: No placebo control reported. Review article — no new primary data.

2006|Journal of neurochemistry
PubMed

Delta sleep-inducing peptide. (European journal of anaesthesiology, 2001)

Limitations: No placebo control reported. Review article — no new primary data.

2001|European journal of anaesthesiology
PubMed

CSF DSIP-LI was significantly correlated with polysomnography the night before the LP: with stage 3 sleep (p = 0.05), stage 3 and delta (stages 3 + 4) sleep during the first nonrapid eye movement NREM period (p = 0.02 and p = 0.05, respectively) and the ratio of the first and second NREM period (p < 0.05), and negatively with stage 2% sleep (p < 0.05). Whether this first report of a potential relationship between CSF DSIP-LI and slow-wave sleep in man might be generalized to sleep in nonpsychiatric subjects awaits further study.

Limitations: No placebo control reported.

1993|Sleep
PubMed

These results suggest that DSIP produces an antinociceptive effect by acting at the supraspinal level and that this effect is mediated via the opioid receptor, either directly or indirectly. DSIP may play an important role in pain regulation in the central nervous system.

Limitations: Animal study only — human translation uncertain.

1989|European journal of pharmacology
PubMed

In all three species, high-performance liquid chromatography revealed a single peak of DSIP-like material with approximately the same retention time as DSIP 3-9. Taken together, the present results provide evidence for the presence of DSIP-LI in gut endocrine cells in man, pig and rat; the human gut seems to be the richest source of DSIP-like peptides.

Limitations: No placebo control reported.

1989|Peptides
PubMed

Significant decreases of DSIP-LI compared with age-matched controls (C1) were observed for S2, S3, MD, PD, VD and H. In contrast, no significant differences corresponding to pathology were found for P-DSIP-LI.

Limitations: Standard limitations apply. Check original paper for full discussion.

1988|Journal of neurology
PubMed

The clearance of DSIP from the ventricles during ventriculo-cisternal perfusion in the rabbit indicated no significant flux of the intact peptide out of the CSF. The results suggest that DSIP crosses the blood-CSF barrier, while the system lacks the specific mechanisms for removal from the CSF found with most, if not all, amino acids and several peptides.

Limitations: Animal study only — human translation uncertain.

1988|Peptides
PubMed

A sleep-related increase in LH release is seen during puberty in man. It is possible that DSIP released within the hypothalamus may play a physiological role in sleep-related LH release.

Limitations: Animal study only — human translation uncertain.

1988|Brain research bulletin
PubMed

Immunohistochemical as well as radioimmunochemical studies provided further insights into the natural occurrence of the nonpeptide and the distribution of DSIP-like material in the body, suggesting possible relations of the peptide to certain diseases. Various physiological functions of DSIP and a possible mechanism of action involving the modulation of adrenergic transmission remain to be established.

Limitations: No placebo control reported. Review article — no new primary data.

1987|Peptides
PubMed

The increase in S2 was caused by a prolongation of S2 episodes and not by their more frequent occurrence. The results obtained suggest a sleep-facilitating property of DSIP.

Limitations: Animal study only — human translation uncertain.

1987|Brain research
PubMed

However, DSIP (10(-8) or 10(-6)M) had no effect on either basal or luteinizing hormone-releasing hormone-induced in vitro LH release from the hemipituitaries of ovarian steroid-primed rats. These findings are in accord with the hypothesis that DSIP or DSIP-like peptide(s) may activate the hypothalamic neural circuitry responsible for stimulation of LH release reported to occur during sleep.

Limitations: Animal study only — human translation uncertain.

1987|Life sciences
PubMed

It was concluded that the rapid disappearance of injected DSIP in blood was due to degradation, whereas complex formation together with slower degradation resulted in longer persistence of apparently intact analogs. Whether this could explain the sometimes stronger and more consistent effects of DSIP-analogs remains to be examined.

Limitations: No placebo control reported.

1987|Peptides
PubMed

There was no change in the amount of REM sleep. These findings support the belief that DSIP can increase sleep wave activity when administered by peripheral route.

Limitations: Animal study only — human translation uncertain.

1987|Physiology &amp; behavior
PubMed

DSIP-like material was found by RIA and immunohistochemistry in brain and by RIA in peripheral organs of the rat as well as in plasma of several mammals. In addition to sleep, the peptide also has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal.

Limitations: No placebo control reported. Review article — no new primary data.

1984|Neuroscience and biobehavioral reviews
PubMed

Digestion with trypsin, however, produced small immunoreactive peptides with only a minimal reduction in total immunoreactivity. Thus, DSIP-like material is widespread in peripheral tissues and appears to exist mainly in a large form, probably bound to protein, that can be reduced in size by tryptic digestion and can be dissociated at lower concentrations of tissue to yield small immunoreactive peptides.

Limitations: Animal study only — human translation uncertain.

1984|Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
PubMed

The results cannot be explained by either regurgitation of intestinal contents, or by stimulation of endogenous peptide. They show that a DSIP peptide administered orally can be absorbed through the GI tract into the systemic circulation.

Limitations: Animal study only — human translation uncertain.

1983|Life sciences
PubMed

Results of 6-day consecutive intravenous administration (50 microgram/kg) indicate that there is no obvious sign of adaptation to DSIP. Results suggest that the physiological function of endogenous sleep-inducing peptide is different from that of general sleeping draught.

Limitations: Animal study only — human translation uncertain.

1983|Scientia Sinica. Series B, Chemical, biological, agricultural, medical &amp; earth sciences
PubMed

Sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated. The study corroborates the findings of previous investigations in healthy subjects and shows that DSIP has a normalizing influence on human sleep regulation.

Limitations: No placebo control reported.

1982|Experientia
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •May cause vivid dreams or nightmares
  • •Paradoxical alertness in some individuals
  • •Not recommended for those with severe depression
  • •Long-term human safety data limited
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get DSIP (Delta Sleep-Inducing Peptide), baseline labs & clinician oversight.

Full DSIP (Delta Sleep-Inducing Peptide) $/mg comparison →
50% OFF AUTO-APPLIED$3.00/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy DSIP (Delta Sleep-Inducing Peptide): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $3.00/mg (10mg Lyophilized Vial, $30.00)
  2. 2. Direct Peptides — $4.90/mg (10mg vial, $49.00)
  3. 3. Elite Research USA — $5.50/mg (10mg vial, $55.00)

Where is the cheapest place to buy DSIP (Delta Sleep-Inducing Peptide)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $3.00/mg (10mg Lyophilized Vial, $30.00 after the 50% new-customer partner-link discount). We compared 10 US suppliers with live, checked prices.

How much does DSIP (Delta Sleep-Inducing Peptide) cost per mg?

Verified US domestic prices currently range from $3.00/mg to $11.19/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is DSIP (Delta Sleep-Inducing Peptide) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.